ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction

Masaaki Doi; Hideto Matsui; Yukiji Takeda; Yoshihiko Saito; Maiko Takeda; Yasunori Matsunari; Kenji Nishio; Midori Shima; Fumiaki Banno; Masashi Akiyama; Koichi Kokame; Toshiyuki Miyata; Mitsuhiko Sugimoto

doi:10.1160/TH12-09-0674

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 108(06): 1236-1238
DOI: 10.1160/TH12-09-0674

Letters to the Editor

Schattauer GmbH

ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction

Masaaki Doi

¹Department of Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Japan

²Department of Pediatrics, Nara Medical University, Kashihara, Japan

,

Hideto Matsui

¹Department of Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Japan

,

Yukiji Takeda

³Department of Internal Medicine, Nara Medical University, Kashihara, Japan

,

Yoshihiko Saito

³Department of Internal Medicine, Nara Medical University, Kashihara, Japan

,

Maiko Takeda

⁴Department of Pathology, Nara Medical University, Kashihara, Japan

,

Yasunori Matsunari

¹Department of Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Japan

⁵Department of Anesthesiology, Nara Medical University, Kashihara, Japan

,

Kenji Nishio

⁶Department of General Medicine, Nara Medical University, Kashihara, Japan

,

Midori Shima

²Department of Pediatrics, Nara Medical University, Kashihara, Japan

,

Fumiaki Banno

⁷Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Osaka, Japan

,

Masashi Akiyama

⁷Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Osaka, Japan

,

Koichi Kokame

⁷Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Osaka, Japan

,

Toshiyuki Miyata

⁷Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Osaka, Japan

,

Mitsuhiko Sugimoto

¹Department of Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Japan

› Author Affiliations

Abstract

Full Text

References

1 Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-1342.
2 Sugimoto M, Matsui H, Mizuno T. et al. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood 2003; 101: 915-920.
3 Lenting PJ, Pegon JN, Groot E. et al. Regulation of von Willebrand factor-platelet interactions. Thromb Haemost 2010; 104: 449-455.
4 Matsui H, Sugimoto M, Mizuno T. et al. Distinct and concerted functions of von Willebrand factor and fibrinogen in mural thrombus growth under high shear flow. Blood 2002; 100: 3604-3610.
5 Shida Y, Nishio K, Sugimoto M. et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 2008; 111: 1295-1298.
6 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
7 Fujioka M, Hayakawa K, Mishima K. et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010; 115: 1650-1653.
8 Zhao B- Q, Chauhan AK, Canault M. et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334.
9 De Meyer SF, Schwarz T, Deckmyn H. et al. Binding of von Willebrand factor to collagen and glycoprotein Ib alpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice. Arterioscler Thromb Vasc Biol 2010; 30: 1949-1951.
10 Banno F, Kokame K, Okuda T. et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-3166.
11 Takeda Y, Uemura S, Iwama H. et al. Treatment with recombinant placental growth factor (PIGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J 2009; 73: 1674-1682.
12 Akiyama M, Takeda S, Kokome K. et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA 2009; 106: 19274-19279.
13 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73. A first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
14 De Meyer SF, Savchenco AS, Haas MS. et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012; Epub ahead of print. doi:10.1182/blood 2012; 06: 439935.
15 Tao Z, Wang Y, Choi H. et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminaltruncated mutants of ADAMTS-13 under flow. Blood 2005; 106: 141-143.
16 Zhang P, Pan W, Rux AH. et al. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110: 1887-1894.
17 Chauhan AK, Kisucka J, Brill A. et al. ADAMTS 13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074.